This stock comparison examines two healthcare insurers operating at different stages of maturity: CNC (Centene Corporation), a large managed care organization with deep exposure to Medicaid and marketplace coverage, and OSCR (Oscar Health), a technology-driven insurer built around the individual ACA market. Both names have benefited from improving underwriting and a more supportive regulatory backdrop in recent weeks, making their relative performance a useful case study for investors weighing scale and stability against growth and momentum. This comparison is relevant to traders monitoring sector rotation in healthcare, as well as longer-horizon investors evaluating market positioning, profitability, and risk across two very different business models. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
CNC, or Centene Corporation, is one of the largest U.S. providers of government-sponsored health plans, with its revenue centered on Medicaid managed care and ACA marketplace products. In recent weeks, the stock has traded within a broad 52-week range that reflects a substantial recovery from earlier lows. Sentiment has been supported by a stronger-than-expected quarterly report in which the company raised its full-year adjusted earnings outlook, along with analyst price-target increases from several research firms. Broader policy developments — including signals that federal Medicaid funding pressure may be easing and a temporary suspension of certain Medicaid work-requirement enforcement — have further reinforced investor confidence. The company's medical cost trends have shown signs of stabilization, which is a key driver of its improving margin narrative. Despite this recovery, Centene remains a low-margin business with meaningful sensitivity to state rate resets and regulatory decisions.
OSCR, or Oscar Health, is a technology-enabled health insurer focused on the individual and small-group ACA markets, supported by its digital platforms and brokerage offerings. Recent market activity has been marked by considerable momentum, with the stock trading near the upper portion of its 52-week range and posting a sharp year-to-date advance. The company recently reported record profitability, swinging from a prior-year loss to positive net income, and raised its full-year operating earnings guidance for the third time this year. Revenue growth has been rapid, driven by higher premium rates and strong membership gains, while its medical loss ratio (the share of premium revenue spent on medical claims) improved meaningfully. This combination of accelerating growth, pricing discipline, and operating leverage has shaped a markedly positive sentiment shift, even as the stock's higher volatility reflects its smaller scale and concentrated exposure to the individual market.
The most important contrast between CNC and OSCR is one of scale versus growth. Centene generates revenue measured in the hundreds of billions annually and derives diversification from Medicaid, Medicare, commercial, and specialty segments. Oscar Health is far smaller, with revenue concentrated in the individual ACA market, but is expanding rapidly and only recently reached sustained profitability. In terms of risk factors, Centene faces exposure to state Medicaid rate resets, medical cost trends, and ongoing legal scrutiny, while Oscar is more exposed to ACA subsidy policy, risk-adjustment transfers, and competitive pricing in the individual market. On market positioning, Centene offers relative stability, reflected in its notably lower beta, whereas Oscar carries higher volatility alongside stronger near-term momentum and faster earnings growth. Neither name pays a dividend, so total return depends on price appreciation.
Weighing trend consistency, relative momentum, and the recent fundamental inflection, a Tickeron AI-driven framework would likely favor OSCR over CNC in the current environment. Oscar Health's combination of record profitability, accelerating revenue growth, improved underwriting ratios, and a stock price trending toward the upper end of its range presents a more consistently positive signal profile. Centene's recovery is genuine but comparatively more mature and encumbered by policy and legal uncertainties. This verdict reflects probabilistic, data-driven positioning rather than a definitive forecast: as market conditions evolve, the relative attractiveness of these two names could shift accordingly. From what I see, the AI Pattern Search Engine helped confirm some of these momentum signals.
In my analysis of these names, I turned to Tickeron’s AI Trading Bots to see how automated strategies have been handling similar healthcare names lately. The platform lets users review performance across different timeframes and risk levels, which adds a useful layer when comparing two stocks with such different profiles. It is not a replacement for fundamental work, but it offers another angle on how systems are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CNC's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In 138 of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 65%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CNC as a result. In 55 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for CNC just turned positive on November 16, 2026. Looking at past instances where CNC's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +6.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in 189 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The 10-day RSI Indicator for CNC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 60 cases where CNC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CNC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CNC's P/B Ratio (1.527) is slightly lower than the industry average of (3.520). P/E Ratio (-6.751) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (0.569).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a multi-line healthcare enterprise
Industry ManagedHealthCare